MONTE ROSA THERAPEUTIC

10.36

29-November-24 12:45:00

15 minutes delayed

Stocks

+1.25

+13.72%

Today's range

9.23 - 10.44

ISIN

N/A

Source

NASDAQ

Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 06:30:01 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

10 Nov 2022 06:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors

01 Nov 2022 06:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

31 Oct 2022 15:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium

20 Oct 2022 15:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader

06 Sep 2022 06:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

11 Aug 2022 06:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

11 May 2022 06:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022

08 Apr 2022 12:00:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

29 Mar 2022 06:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

03 Feb 2022 15:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders

25 Jan 2022 06:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

02 Dec 2021 06:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

22 Nov 2021 06:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates

10 Nov 2021 06:30:01 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit

20 Oct 2021 06:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer

07 Oct 2021 08:00:02 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference

30 Sep 2021 15:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes

10 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.